Search Results - "PROVENCHER, Diane"

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial by Monk, Bradley J, Prof, Poveda, Andrés, MD, Vergote, Ignace, MD, Raspagliesi, Francesco, MD, Fujiwara, Keiichi, MD, Bae, Duk-Soo, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, MD, Provencher, Diane M, MD, Karlan, Beth Y, MD, Lhommé, Catherine, MD, Richardson, Gary, MD, Rincón, Dolores Gallardo, MD, Coleman, Robert L, MD, Herzog, Thomas J, MD, Marth, Christian, PhD, Brize, Arija, MD, Fabbro, Michel, MD, Redondo, Andrés, MD, Bamias, Aristotelis, PhD, Tassoudji, Marjan, MS, Navale, Lynn, MS, Warner, Douglas J, MD, Oza, Amit M, MD

“…Summary Background Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to…”
Get full text

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence by Fleury, Hubert, Malaquin, Nicolas, Tu, Véronique, Gilbert, Sophie, Martinez, Aurélie, Olivier, Marc-Alexandre, Sauriol, Skye Alexandre, Communal, Laudine, Leclerc-Desaulniers, Kim, Carmona, Euridice, Provencher, Diane, Mes-Masson, Anne-Marie, Rodier, Francis

“…Senescence is a tumor suppression mechanism defined by stable proliferation arrest. Here we demonstrate that the known synthetic lethal interaction between…”
Get full text

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models by Brodeur, Melica Nourmoussavi, Simeone, Kayla, Leclerc-Deslauniers, Kim, Fleury, Hubert, Carmona, Euridice, Provencher, Diane M., Mes-Masson, Anne-Marie

“…Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Among the key challenges in developing effective therapeutics is the poor translation…”
Get full text

Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion by Zaoui, Kossay, Boudhraa, Zied, Khalifé, Paul, Carmona, Euridice, Provencher, Diane, Mes-Masson, Anne-Marie

“…Ran is a nucleocytoplasmic shuttle protein that is involved in cell cycle regulation, nuclear-cytoplasmic transport, and cell transformation. Ran plays an…”
Get full text

BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis by Le Page, Cécile, Marineau, Alexandre, Bonza, Patrick K, Rahimi, Kurosh, Cyr, Louis, Labouba, Ingrid, Madore, Jason, Delvoye, Nathalie, Mes-Masson, Anne-Marie, Provencher, Diane M, Cailhier, Jean-François

“…BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small cohort of high grade serous epithelial…”
Get full text

Author Correction: Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer by Sauriol, Skye Alexandre, Carmona, Euridice, Udaskin, Molly L., Radulovich, Nikolina, Leclerc-Desaulniers, Kim, Rottapel, Robert, Oza, Amit M., Lheureux, Stephanie, Provencher, Diane M., Mes-Masson, Anne-Marie

Get full text

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer by Oza, Amit M, Matulonis, Ursula A, Alvarez Secord, Angeles, Nemunaitis, John, Roman, Lynda D, Blagden, Sarah P, Banerjee, Susana, McGuire, William P, Ghamande, Sharad, Birrer, Michael J, Fleming, Gini F, Markham, Merry Jennifer, Hirte, Hal W, Provencher, Diane M, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah K, Schwartz, Benjamin, Braly, Patricia, Hall, Geoff D, Nephew, Kenneth P, Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

“…Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing…”
Get full text

Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer by Sauriol, Skye Alexandre, Carmona, Euridice, Udaskin, Molly L., Radulovich, Nikolina, Leclerc-Desaulniers, Kim, Rottapel, Robert, Oza, Amit M., Lheureux, Stephanie, Provencher, Diane M., Mes-Masson, Anne-Marie

“…Epithelial ovarian cancer is the most lethal gynecological malignancy, owing notably to its high rate of therapy-resistant recurrence in spite of good initial…”
Get full text

A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis by Communal, Laudine, Roy, Noemi, Cahuzac, Maxime, Rahimi, Kurosh, Köbel, Martin, Provencher, Diane M., Mes-Masson, Anne-Marie

“…During tubo-ovarian high-grade serous carcinoma (HGSC) progression, tumoral cells undergo phenotypic changes in their epithelial marker profiles, which are…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer by KARLAN, Beth Y, OZA, Amit M, COVENS, Allan, NAGARKAR, Raj V, DAVY, Margaret, LEATH, Charles A, NGUYEN, Hoa, STEPAN, Daniel E, WEINREICH, David M, TASSOUDJI, Marjan, SUN, Yu-Nien, VERGOTE, Ignace B, RICHARDSON, Gary E, PROVENCHER, Diane M, HANSEN, Vincent L, BUCK, Martin, CHAMBERS, Setsuko K, GHATAGE, Prafull, PIPPITT, Charles H, BROWN, John V

“…To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and…”
Get full text

Ran GTPase: A Key Player in Tumor Progression and Metastasis by Boudhraa, Zied, Carmona, Euridice, Provencher, Diane, Mes-Masson, Anne-Marie

“…Ran (Ras-related nuclear protein) GTPase is a member of the Ras superfamily. Like all the GTPases, Ran cycles between an active (GTP-bound) and inactive…”
Get full text

Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk by Leung, Lisa, Grundy, Anne, Siemiatycki, Jack, Arseneau, Jocelyne, Gilbert, Lucy, Gotlieb, Walter H, Provencher, Diane M, Aronson, Kristan J, Koushik, Anita

“…Shift work causing circadian disruption is classified as a "probable carcinogen" and may contribute to the pathogenesis of hormone-sensitive cancers. This…”
Get full text

Lifetime recreational moderate‐to‐vigorous physical activity and ovarian cancer risk: A case–control study by Grundy, Anne, Ho, Vikki, Abrahamowicz, Michal, Parent, Marie‐Élise, Siemiatycki, Jack, Arseneau, Jocelyne, Gilbert, Lucy, Gotlieb, Walter H., Provencher, Diane M., Koushik, Anita

“…Results of epidemiologic studies of physical activity and ovarian cancer risk are inconsistent. Few have attempted to measure physical activity over the…”
Get full text

Author Correction: Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence by Fleury, Hubert, Malaquin, Nicolas, Tu, Véronique, Gilbert, Sophie, Martinez, Aurélie, Olivier, Marc-Alexandre, Sauriol, Skye Alexandre, Communal, Laudine, Leclerc-Desaulniers, Kim, Carmona, Euridice, Provencher, Diane, Mes-Masson, Anne-Marie, Rodier, Francis

Get full text

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers by Le Page, Cécile, Rahimi, Kurosh, Köbel, Martin, Tonin, Patricia N, Meunier, Liliane, Portelance, Lise, Bernard, Monique, Nelson, Brad H, Bernardini, Marcus Q, Bartlett, John M S, Bachvarov, Dimcho, Gotlieb, Walter H, Gilks, Blake, McAlpine, Jessica N, Nachtigal, Mark W, Piché, Alain, Watson, Peter H, Vanderhyden, Barbara, Huntsman, David G, Provencher, Diane M, Mes-Masson, Anne-Marie

“…Ovarian carcinoma is the most lethal gynecological malignancy due to early dissemination and acquired resistance to platinum-based chemotherapy. Reliable…”
Get full text

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors) by Harter, Philipp, Gershenson, David, Lhomme, Catherine, Lecuru, Fabrice, Ledermann, Jonathan, Provencher, Diane M, Mezzanzanica, Delia, Quinn, Michael, Maenpaa, Johanna, Kim, Jae-Weon, Mahner, Sven, Hilpert, Felix, Baumann, Klaus, Pfisterer, Jacobus, du Bois, Andreas

“…Since the early 1970s, the World Health Organization and the International Federation of Gynecology and Obstetrics have classified borderline ovarian tumors as…”
Get more information

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems by Patra, Bishnubrata, Lateef, Muhammad Abdul, Brodeur, Melica Nourmoussavi, Fleury, Hubert, Carmona, Euridice, Péant, Benjamin, Provencher, Diane, Mes-Masson, Anne-Marie, Gervais, Thomas

“…Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in North America, underscoring the need for the development of new therapeutic…”
Get full text

Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix by Satoh, Toyomi, Takei, Yuji, Treilleux, Isabelle, Devouassoux-Shisheboran, Mojgan, Ledermann, Jonathan, Viswanathan, Akila N, Mahner, Sven, Provencher, Diane M, Mileshkin, Linda, Åvall-Lundqvist, Elizabeth, Pautier, Patricia, Reed, Nicholas Simon, Fujiwara, Keiichi

“…Small cell carcinoma of the cervix (SCCC) is a rare histological entity of uterine cervical cancer. Compared with other common histological types, squamous…”
Get more information

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2 by Monk, Bradley J, Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M, Karlan, Beth Y, Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L, Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Ma, Haijun, Vogl, Florian D, Bach, Bruce A, Oza, Amit M

“…Abstract Purpose Trebananib, a peptibody that blocks binding of angiopoietin-1 and -2 to Tie2, significantly prolonged progression-free survival (PFS) in…”
Get full text

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma by Sagae, Satoru, Susumu, Nobuyuki, Viswanathan, Akila N, Aoki, Daisuke, Backes, Floor J, Provencher, Diane M, Vaughan, Michelle, Creutzberg, Carien L, Kurzeder, Christian, Kristensen, Gunnar, Lee, Chulmin, Kurtz, Jean-Emmanuel, Glasspool, Rosalind M, Small, Jr, William

“…Uterine serous carcinoma (USC) represents a rare and aggressive histologic subtype of endometrial cancer, associated with a poor prognosis. This article…”
Get more information